Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H16ClN3O |
Molecular Weight | 313.781 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=CC2=C(OC3=C(C=CC=C3)N=C2N4CCNCC4)C=C1
InChI
InChIKey=QWGDMFLQWFTERH-UHFFFAOYSA-N
InChI=1S/C17H16ClN3O/c18-12-5-6-15-13(11-12)17(21-9-7-19-8-10-21)20-14-3-1-2-4-16(14)22-15/h1-6,11,19H,7-10H2
Molecular Formula | C17H16ClN3O |
Molecular Weight | 313.781 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Amoxapine is an antidepressant of the dibenzoxazepine class, chemically distinct from the dibenzazepines, dibenzocycloheptenes, and dibenzoxepines. It is designated chemically as 2-Chloro-11- (1-piperazinyl)dibenz[b,f ][1,4]oxazepine. Amoxapine is an antidepressant with a mild sedative component to its action. The mechanism of its clinical action in man is not well understood. In animals, amoxapine reduced the uptake of norepinephrine and serotonin and blocked the response of dopamine receptors to dopamine. Amoxapine is not a monoamine oxidase inhibitor. Amoxapine is absorbed rapidly and reaches peak blood levels approximately 90 minutes after ingestion. It is almost completely metabolized. The main route of excretion is the kidney. In vitro tests show that amoxapine binding to human serum is approximately 90%. In man, amoxapine serum concentration declines with a half-life of eight hours. However, the major metabolite, 8-hydroxyamoxapine, has a biologic half-life of 30 hours. Metabolites are excreted in the urine in conjugated form as glucuronides. Clinical studies have demonstrated that amoxapine has a more rapid onset of action than either amitriptyline or imipramine. The initial clinical effect may occur within four to seven days and occurs within two weeks in over 80% of responders.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2096905 |
|||
Target ID: CHEMBL222 |
|||
Target ID: CHEMBL228 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15655900 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | AMOXAPINE Approved UseAmoxapine is indicated for the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. It is indicated for depression accompanied by anxiety or agitation. Launch Date7.1487357E11 |
|||
Primary | AMOXAPINE Approved UseAmoxapine is indicated for the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. It is indicated for depression accompanied by anxiety or agitation. Launch Date7.1487357E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
33.55 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3997304/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMOXAPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
319 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3997304/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMOXAPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6.02 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3997304/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMOXAPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3997304/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMOXAPINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
Doses
Dose | Population | Adverse events |
---|---|---|
300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Other AEs: Ataxia, Drowsiness... Other AEs: Ataxia (>1) Sources: Drowsiness (14%) Dry mouth (14%) Constipation (12%) Blurred vision (7%) Anxiety (>1) Insomnia (>1) Nervousness (>1) Nightmare (>1) Restlessness (>1) Palpitations (>1) Tremor (>1) Confusion (>1) Excitement (>1) Edema (>1) Skin rash (>1) Prolactin increased (>1) Nausea (>1) Dizziness (>1) Headache (>1) Fatigue (>1) Weakness (>1) Appetite excessive (>1) Perspiration excessive (>1) Accommodation disturbance (<1%) Mydriasis (<1%) Micturition disorder (<1%) Urinary retention (<1%) Nasal stuffiness (<1%) Hypotension (<1%) Hypertension (<1%) Syncope (<1%) Tachycardia (<1%) Drug fever (<1%) Urticaria (<1%) Photosensitized (<1%) Pruritus (<1%) Vasculitis (<1%) Hepatitis (<1%) Tingling (<1%) Tinnitus (<1%) Disorientation (<1%) Seizures (<1%) Hypomania (<1%) Numbness (<1%) Incoordination (<1%) Concentration impairment (<1%) Hyperthermia (<1%) Extrapyramidal symptoms (<1%) Tardive dyskinesia (<1%) Leukopenia (<1%) Agranulocytosis (<1%) Epigastric distress (<1%) Vomiting (<1%) Flatulence (<1%) Abdominal pain (<1%) Taste peculiar (<1%) Diarrhea (<1%) Impotence (<1%) Menstrual irregularity (<1%) Breast enlargement (<1%) Inappropriate antidiuretic hormone secretion (<1%) Galactorrhea (<1%) Lacrimation (<1%) Weight gain (<1%) Weight loss (<1%) Impaired liver function (<1%) Painful ejaculation (<1%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Constipation | 12% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Drowsiness | 14% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Dry mouth | 14% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Blurred vision | 7% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Abdominal pain | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Accommodation disturbance | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Agranulocytosis | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Breast enlargement | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Concentration impairment | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Diarrhea | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Disorientation | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Drug fever | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Epigastric distress | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Extrapyramidal symptoms | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Flatulence | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Galactorrhea | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Hepatitis | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Hypertension | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Hyperthermia | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Hypomania | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Hypotension | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Impaired liver function | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Impotence | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Inappropriate antidiuretic hormone secretion | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Incoordination | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Lacrimation | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Leukopenia | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Menstrual irregularity | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Micturition disorder | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Mydriasis | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Nasal stuffiness | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Numbness | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Painful ejaculation | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Photosensitized | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Pruritus | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Seizures | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Syncope | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Tachycardia | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Tardive dyskinesia | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Taste peculiar | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Tingling | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Tinnitus | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Urinary retention | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Urticaria | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Vasculitis | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Vomiting | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Weight gain | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Weight loss | <1% | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Anxiety | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Appetite excessive | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Ataxia | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Confusion | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Dizziness | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Edema | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Excitement | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Fatigue | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Headache | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Insomnia | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Nausea | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Nervousness | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Nightmare | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Palpitations | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Perspiration excessive | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Prolactin increased | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Restlessness | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Skin rash | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Tremor | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
Weakness | >1 | 300 mg 1 times / day steady, oral Dose: 300 mg, 1 times / day Route: oral Route: steady Dose: 300 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: depression Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Amoxapine-associated acute renal failure. | 1985 Jun |
|
Amoxapine-induced cognitive impairment in two patients. | 1987 Apr |
|
Acute myocardial failure following amoxapine intoxication. | 1988 Feb |
|
Meta-analytical studies on new antidepressants. | 2001 |
|
Availability of learned helplessness test as a model of depression compared to a forced swimming test in rats. | 2001 |
|
[Delusional depression]. | 2001 Aug |
|
Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine. | 2001 Dec 27 |
|
Further characterization of 5-HT1A receptors in the goldfish retina: role of cyclic AMP in the regulation of the in vitro outgrowth of retinal explants. | 2001 Mar |
|
Glycine is taken up through GLYT1 and GLYT2 transporters into mouse spinal cord axon terminals and causes vesicular and carrier-mediated release of its proposed co-transmitter GABA. | 2001 Mar |
|
Painful ejaculation and urinary hesitancy in association with antidepressant therapy: relief with tamsulosin. | 2002 Aug |
|
The effects of tricyclic antidepressants on breast cancer risk. | 2002 Jan 7 |
|
Survey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patterns. | 2004 Apr 27 |
|
Risk of fetal exposure to tricyclic antidepressants. | 2004 Oct |
|
The pharmacological management of depression. | 2005 |
|
Amoxapine as an atypical antipsychotic: a comparative study vs risperidone. | 2005 Dec |
|
Facilitation of spontaneous glutamate release by antidepressant drugs in rat locus coeruleus. | 2005 Feb 10 |
|
Detection and treatment of akathisia in advanced cancer patients during adjuvant analgesic therapy with tricyclic antidepressants: case reports and review of the literature. | 2007 Dec |
|
Amoxapine as an antipsychotic: comparative study versus haloperidol. | 2007 Dec |
|
A fatal case of amoxapine poisoning under the influence of chronic use of psychotropic drugs. | 2007 Mar |
|
Differential distribution of glycine transporters in Müller cells and neurons in amphibian retinas. | 2007 Mar-Apr |
|
Prevalence and predictors of antidepressant use in a cohort of pregnant women. | 2007 Sep |
|
An autopsy case of poisoning with ethanol and psychotropic drugs. | 2008 Apr |
|
Functional expression of the glycine transporter 1 on bullfrog retinal cones. | 2008 Nov 19 |
|
Amoxapine-induced tardive dyskinesia. | 2009 Oct-Dec |
|
A new strategy for antidepressant prescription. | 2010 |
|
Direct agonist activity of tricyclic antidepressants at distinct opioid receptor subtypes. | 2010 Jan |
|
Drug-drug interaction between oxycodone and adjuvant analgesics in blood-brain barrier transport and antinociceptive effect. | 2010 Jan |
|
Tricyclic antidepressants and headaches: systematic review and meta-analysis. | 2010 Oct 20 |
Sample Use Guides
Usual effective dosage is 200 to 300 mg daily. Three weeks constitutes an adequate period of trial providing dosage has reached 300 mg daily (or lower level of tolerance) for at least two weeks. If no response is seen at 300 mg, dosage may be increased, depending upon tolerance, up to 400 mg daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19915071
Cells (mouse cortical neurons) were incubated with or without amoxapine varying concentrations of 10, 50, and 100 uM. At a concentration of 10 to 500 uM, amoxapine reversibly inhibited I(K) in a dose-dependent manner and modulated both steady-state activation and inactivation properties.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 17 01:42:53 UTC 2022
by
admin
on
Sat Dec 17 01:42:53 UTC 2022
|
Record UNII |
R63VQ857OT
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QN06AA17
Created by
admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
|
||
|
NDF-RT |
N0000175752
Created by
admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
|
||
|
WHO-ATC |
N06AA17
Created by
admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
|
||
|
LIVERTOX |
NBK548520
Created by
admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
|
||
|
NCI_THESAURUS |
C94727
Created by
admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
191
Created by
admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
|
PRIMARY | |||
|
SUB05479MIG
Created by
admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
|
PRIMARY | |||
|
Amoxapine
Created by
admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
|
PRIMARY | |||
|
722
Created by
admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
|
PRIMARY | RxNorm | ||
|
R63VQ857OT
Created by
admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
|
PRIMARY | |||
|
14028-44-5
Created by
admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
|
PRIMARY | |||
|
1031401
Created by
admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
|
PRIMARY | |||
|
201
Created by
admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
|
PRIMARY | |||
|
M1843
Created by
admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
|
PRIMARY | Merck Index | ||
|
2675
Created by
admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
|
PRIMARY | |||
|
237-867-1
Created by
admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
|
PRIMARY | |||
|
3049
Created by
admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
|
PRIMARY | |||
|
DB00543
Created by
admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
|
PRIMARY | |||
|
759559
Created by
admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
|
PRIMARY | |||
|
DTXSID7022598
Created by
admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
|
PRIMARY | |||
|
Amoxapine
Created by
admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
|
PRIMARY | |||
|
R63VQ857OT
Created by
admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
|
PRIMARY | |||
|
2170
Created by
admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
|
PRIMARY | |||
|
D000657
Created by
admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
|
PRIMARY | |||
|
CHEMBL1113
Created by
admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
|
PRIMARY | |||
|
C47397
Created by
admin on Sat Dec 17 01:42:53 UTC 2022 , Edited by admin on Sat Dec 17 01:42:53 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BINDER->LIGAND |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
||
|
PARENT -> METABOLITE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||